Items by Cami-Kobeci, Gerta
 | Up a level |
Number of items: 10.
Zielińska, M., Jarmuż, A., Wasilewski, A., Cami-Kobeci, G., Husbands, S. and Fichna, J., 2017. Methyl-orvinol—Dual activity opioid receptor ligand inhibits gastrointestinal transit and alleviates abdominal pain in the mouse models mimicking diarrhea-predominant irritable bowel syndrome. Pharmacological Reports, 69 (2), pp. 350-357. Item availability may be restricted.
Ding, H., Czoty, P. W., Kiguchi, N., Cami-Kobeci, G., Sukhtankar, D. D., Nader, M. A., Husbands, S. M. and Ko, M.-C., 2016. A novel orvinol analog, BU08028, as a safe opioid analgesic without abuse liability in primates. Proceedings of the National Academy of Sciences of the United States of America
Khroyan, T. V., Wu, J., Polgar, W. E., Cami-Kobeci, G., Fotaki, N., Husbands, S. M. and Toll, L., 2015. BU08073 a buprenorphine analog with partial agonist activity at μ-receptors in vitro but long-lasting opioid antagonist activity in vivo in mice. British Journal of Pharmacology, 172 (2), pp. 668-680.
Sobczak, M., Cami-Kobeci, G., Sałaga, M., Husbands, S. M. and Fichna, J., 2014. Novel mixed NOP/MOP agonist BU08070 alleviates pain and inhibits gastrointestinal motility in mouse models mimicking diarrhea-predominant irritable bowel syndrome symptoms. European Journal of Pharmacology, 736, pp. 63-69.
Greedy, B. M., Bradbury, F., Thomas, M. P., Grivas, K., Cami-Kobeci, G., Archambeau, A., Bosse, K., Clark, M. J., Aceto, M., Lewis, J. W., Traynor, J. R. and Husbands, S. M., 2013. Orvinols with mixed kappa/mu opioid receptor agonist activity. Journal of Medicinal Chemistry, 56 (8), pp. 3207-3216.
Cami-Kobeci, G., Polgar, W. E., Khroyan, T. V., Toll, L. and Husbands, S. M., 2011. Structural determinants of opioid and NOP receptor activity in derivatives of buprenorphine. Journal of Medicinal Chemistry, 54 (19), pp. 6531-6537.
Khroyan, T. V., Polgar, W. E., Cami-Kobeci, G., Husbands, S. M., Zaveri, N. T. and Toll, L., 2011. The first universal opioid ligand, (2S)-2- (5R,6R,7R,14S)-N-cyclopropylmethyl-4,5-epoxy-6,14-ethano-3-hydro xy-6-methoxymorphinan-7-yl -3,3-dimethylpentan-2-ol (BU08028): Characterization of the in vitro profile and in vivo behavioral effects in mouse models of acute pain and cocaine-induced reward. Journal of Pharmacology and Experimental Therapeutics, 336 (3), pp. 952-961.
Cami-Kobeci, G., Polgar, W. E., Khroyan, T. V., Toll, L. and Husbands, S. M., 2011. Universal opioid receptor ligands - buprenorphine and related orvinols. Pharmacological Reports, 63 (1), p. 210.
Cami-Kobeci, G., Neale, A. P., Bradbury, F. A., Purington, L. C., Aceto, M. D., Harris, L. S., Lewis, J. W., Traynor, J. R. and Husbands, S. M., 2009. Mixed κ/μ Opioid Receptor Agonists: The 6β-Naltrexamines. Journal of Medicinal Chemistry, 52 (6), pp. 1546-1552.
Rennison, D., Neal, A. P., Cami-Kobeci, G., Aceto, M. D., Martinez-Bermejo, F., Lewis, J. W. and Husbands, S. M., 2007. Cinnamoyl Derivatives of 7α-Aminomethyl-6,14-endoethanotetrahydrothebaine and 7α-Aminomethyl-6,14-endoethanotetrahydrooripavine and Related Opioid Ligands. Journal of Medicinal Chemistry, 50 (21), pp. 5176-5182.
